IDEXX Laboratories, Inc. IDXX

519.26 5.87 1.14% as of 25 Sep
Market cap
$40.2B
P/E
36.2×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

IDEXX Laboratories, Inc. (IDXX) EV/EBITDA

As of 25 September 2026, IDEXX Laboratories, Inc. (IDXX) trades at a EV/EBITDA of 25.6×. Over the past ten years it has ranged from 16.9× (January 2016) to 63.2× (August 2021); the current reading is higher than 16% of that period. That is in line with the Diagnostics & Research industry median of 25.2× and above the Healthcare sector median of 10.4×.

EV/EBITDA, daily

Annual

Period EV/EBITDA Change
FY2025 36.3× 32.78%
FY2024 27.4× (27.50%)
FY2023 37.7× 10.20%
FY2022 34.2× (37.51%)
FY2021 54.8× 0.31%
FY2020 54.6× 49.61%
FY2019 36.5× 26.09%
FY2018 29.0× 2.73%
FY2017 28.2× 12.52%
FY2016 25.1× 32.37%

Quarterly

Period EV/EBITDA Change
Jun 2026 25.9× (10.41%)
Mar 2026 28.9× (20.33%)
Dec 2025 36.3× 2.04%
Sep 2025 35.6× 14.02%
42 more quarters

Against its own ten years

Low 16.9× High 63.2×
Ten-year median 33.6×
Current reading's percentile 16

EV/EBITDA against peers

Company EV/EBITDA
NTRA Natera, Inc. compare n/m
GH Guardant Health, Inc. compare n/m
DGX Quest Diagnostics Incorporated compare 14.1×
IQV IQVIA Holdings Inc. compare 17.3×
MTD Mettler-Toledo International, Inc. compare 24.9×
IDXX IDEXX Laboratories, Inc. 25.6×
A Agilent Technologies, Inc. compare 26.5×
ILMN Illumina, Inc. compare 36.0×
WAT Waters Corporation compare 49.8×
Diagnostics & Research industry median 25.2×
Healthcare sector median 10.4×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on IDXX